Table of Contents
Advances in Hepatology
Volume 2014, Article ID 357287, 15 pages
http://dx.doi.org/10.1155/2014/357287
Review Article

Noninvasive Biomarkers of Liver Fibrosis: An Overview

Fellowship of American College of Physicians (FACP) and Arab Board and Saudi Board of Internal Medicine, Medical Department, King AbdulAziz University Hospital, P.O. Box 80215, Jeddah 21589, Saudi Arabia

Received 14 October 2013; Revised 11 January 2014; Accepted 27 February 2014; Published 15 April 2014

Academic Editor: Ned Snyder

Copyright © 2014 Hind I. Fallatah. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. J. McMahon, “The natural history of chronic hepatitis B virus infection,” Hepatology, vol. 49, no. 5, pp. S45–S55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Lavanchy, “The global burden of hepatitis C,” Liver International, vol. 29, supplement 1, pp. 74–81, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. A. C. Moorman, S. C. Gordon, L. B. Rupp et al., “Baseline characteristics and mortality among people in care for chronic hepatitis: the chronic hepatitis cohort study,” Clinical Infectious Diseases, vol. 56, no. 1, pp. 40–50, 2012. View at Publisher · View at Google Scholar
  4. F. Cainelli, “Liver diseases in developing countries,” World Journal of Hepatology, vol. 4, no. 3, pp. 66–67, 2012. View at Publisher · View at Google Scholar
  5. X. Hu, Y. Huang, Z. Bao et al., “Prevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units,” BMC Gastroenterology, vol. 12, article 123, 2012. View at Publisher · View at Google Scholar
  6. A. A. Bravo, S. G. Sheth, and S. Chopra, “Liver biopsy,” The New England Journal of Medicine, vol. 344, no. 7, pp. 495–500, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Baranova, P. Lal, A. Birerdinc, and Z. M. Younossi, “Non-invasive markers for hepatic fibrosis,” BMC Gastroenterology, vol. 11, article 91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Bataller and D. A. Brenner, “Liver fibrosis,” The Journal of Clinical Investigation, vol. 115, no. 2, pp. 209–218, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. R. G. Knodell, K. G. Ishak, and W. C. Black, “Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis,” Hepatology, vol. 1, no. 5, pp. 431–435, 1981. View at Google Scholar · View at Scopus
  10. R. A. Standish, E. Cholongitas, A. Dhillon, A. K. Burroughs, and A. P. Dhillon, “An appraisal of the histopathological assessment of liver fibrosis,” Gut, vol. 55, no. 4, pp. 569–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. P. J. Scheuer, “Classification of chronic viral hepatitis: a need for reassessment,” Journal of Hepatology, vol. 13, no. 3, pp. 372–374, 1991. View at Google Scholar · View at Scopus
  12. G. Sebastiani and A. Alberti, “Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy,” World Journal of Gastroenterology, vol. 12, no. 23, pp. 3682–3694, 2006. View at Google Scholar · View at Scopus
  13. G. Sebastiani, “Non-invasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms,” World Journal of Gastroenterology, vol. 15, no. 18, pp. 2190–2203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Castera, “Assessing liver fibrosis,” Expert Review of Gastroenterology & Hepatology, vol. 2, no. 4, pp. 541–552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. P. Jarcuska, M. Janicko, E. Veselíny, P. Jarcuska, and L. Skladaný, “Circulating markers of liver fibrosis progression,” Clinica Chimica Acta, vol. 411, no. 15-16, pp. 1009–1017, 2010. View at Publisher · View at Google Scholar
  16. L. Castera, “Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease,” Best Practice and Research: Clinical Gastroenterology, vol. 25, no. 2, pp. 291–303, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Parkes, I. N. Guha, P. Roderick, and W. Rosenberg, “Performance of serum marker panels for liver fibrosis in chronic hepatitis C,” Journal of Hepatology, vol. 44, no. 3, pp. 462–474, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Pinzani, F. Vizzutti, U. Arena, and F. Marra, “Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography,” Nature Clinical Practice Gastroenterology & Hepatology, vol. 5, no. 2, pp. 95–106, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. H. H. Chi, C. Verveer, B. E. Hansen, P. E. Zondervan, H. L. A. Janssen, and R. J. de Knegt, “Exclusion of the percutaneous liver biopsy from the management of chronic hepatitis B and C patients: are essential secondary diagnosis being missed?” Journal of Hepatology, vol. 56, supplement 2, pp. S411–S412, 2012. View at Publisher · View at Google Scholar
  20. M. Pinzani, “Noninvasive methods for the assessment of liver fibrosis: a window open on the future?” Hepatology, vol. 54, no. 4, pp. 1476–1477, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Regev, M. Berho, L. J. Jeffers et al., “Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection,” The American Journal of Gastroenterology, vol. 97, no. 10, pp. 2614–2618, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. R. A. Standish, E. Cholongitas, A. Dhillon, A. K. Burroughs, and A. P. Dhillon, “An appraisal of the histopathological assessment of liver fibrosis,” Gut, vol. 55, no. 4, pp. 569–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Castera and M. Pinzani, “Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango?” Gut, vol. 59, no. 7, pp. 861–866, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. M. P. Manns, A. J. Czaja, J. D. Gorham et al., “Diagnosis and management of autoimmune hepatitis,” Hepatology, vol. 51, no. 6, pp. 2193–2213, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. S. L. Friedman, “Liver fibrosis—from bench to bedside,” Journal of Hepatology, vol. 38, supplement 1, pp. S38–S53, 2003. View at Google Scholar · View at Scopus
  26. S. L. Friedman, “Mechanisms of hepatic fibrogenesis,” Gastroenterology, vol. 134, no. 6, pp. 1655–1669, 2008. View at Publisher · View at Google Scholar
  27. M. Pinzani, K. Rombouts, and S. Colagrande, “Fibrosis in chronic liver diseases: diagnosis and management,” Journal of Hepatology, vol. 42, supplement 1, pp. S22–S36, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Gallorini, M. Plebani, P. Pontisso et al., “Serum markers of hepatic fibrogenesis in chronic hepatitis type C treated with alfa-2A interferon,” Liver, vol. 14, no. 5, pp. 257–264, 1994. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-C. Trinchet, D. J. Hartmann, D. Pateron et al., “Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis: relationship to liver histology and conventional liver tests,” Journal of Hepatology, vol. 12, no. 2, pp. 139–144, 1991. View at Google Scholar · View at Scopus
  30. O. Niemelä, J. E. Blake, and H. Orrego, “Serum type I collagen propeptide and severity of alcoholic liver disease,” Alcoholism: Clinical and Experimental Research, vol. 16, no. 6, pp. 1064–1067, 1992. View at Publisher · View at Google Scholar · View at Scopus
  31. C. S. Lieber, D. G. Weiss, and F. Paronetto, “Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease,” Alcoholism: Clinical and Experimental Research, vol. 32, no. 6, pp. 1031–1039, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Tamura, A. Matsuda, N. Kidoguchi, O. Matsumura, T. Mitarai, and K. Isoda, “A family with two sisters with collagenofibrotic glomerulonephropathy,” American Journal of Kidney Diseases, vol. 27, no. 4, pp. 588–595, 1996. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Annoni, M. Colombo, M. C. Cantaluppi, B. Khlat, P. Lampertico, and M. Rojkind, “Serum Type III procollagen peptide and laminin (Lam-P1) detect alcoholic hepatitis in chronic alcohol abusers,” Hepatology, vol. 9, no. 5, pp. 693–697, 1989. View at Google Scholar · View at Scopus
  34. G. Montalto, M. Soresi, F. Aragona et al., “Procollagen III peptide and laminin in chronic viral liver disease,” Presse Medicale, vol. 25, no. 2, pp. 59–62, 1996. View at Google Scholar · View at Scopus
  35. G. B. Gabrielli, F. Capra, M. Casaril et al., “Serum laminin and type III procollagen in chronic hepatitis C. Diagnostic value in the assessment of disease activity and fibrosis,” Clinica Chimica Acta, vol. 265, no. 1, pp. 21–31, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Guéchot, A. Laudat, A. Loria, L. Serfaty, R. Poupon, and J. Giboudeau, “Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis,” Clinical Chemistry, vol. 42, no. 4, pp. 558–563, 1996. View at Google Scholar · View at Scopus
  37. R. Beukers, R. A. A. van Zanten, and S. W. Schalm, “Serial determination of type III procollagen amino propeptide serum levels in patients with histologically progressive and non-progressive primary biliary cirrhosis,” Journal of Hepatology, vol. 14, no. 1, pp. 22–29, 1992. View at Google Scholar · View at Scopus
  38. A. J. McCullough, W. N. Stassen, R. H. Wiesner, and A. J. Czaja, “Serial determinations of the amino-terminal peptide of type III procollagen in severe chronic active hepatitis,” Journal of Laboratory and Clinical Medicine, vol. 109, no. 1, pp. 55–61, 1987. View at Google Scholar · View at Scopus
  39. Y. Murawaki, M. Koda, K. Okamoto, K. Mimura, and H. Kawasaki, “Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C,” Journal of Gastroenterology and Hepatology, vol. 16, no. 7, pp. 777–781, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. T. Ueno, S. Inuzuka, T. Torimura et al., “Significance of serum type-IV collagen levels in various liver diseases. Measurement with a one-step sandwich enzyme immunoassay using monoclonal antibodies with specificity for pepsin-solubilized type-IV collagen,” Scandinavian Journal of Gastroenterology, vol. 27, no. 6, pp. 513–520, 1992. View at Google Scholar · View at Scopus
  41. H. Sakugawa, T. Nakayoshi, K. Kobashigawa et al., “Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 11, no. 2, pp. 255–259, 2005. View at Google Scholar · View at Scopus
  42. K. M. Walsh, A. Fletcher, R. N. M. MacSween, and A. J. Morris, “Basement membrane peptides as markers of liver disease in chronic hepatitis C,” Journal of Hepatology, vol. 32, no. 2, pp. 325–330, 2000. View at Publisher · View at Google Scholar · View at Scopus
  43. J. R. E. Fraser, T. C. Laurent, and U. B. G. Laurent, “Hyaluronan: its nature, distribution, functions and turnover,” Journal of Internal Medicine, vol. 242, no. 1, pp. 27–33, 1997. View at Google Scholar · View at Scopus
  44. G. Montazeri, A. Estakhri, M. Mohamadnejad et al., “Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B,” BMC Gastroenterology, vol. 5, article 32, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Vizzutti, U. Arena, V. Nobili et al., “Non-invasive assessment of fibrosis in non-alcoholic fatty liver disease,” Annals of Hepatology, vol. 8, no. 2, pp. 89–94, 2009. View at Google Scholar · View at Scopus
  46. S. Naveau, B. Raynard, V. Ratziu et al., “Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease,” Clinical Gastroenterology and Hepatology, vol. 3, no. 2, pp. 167–174, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Murawaki, Y. Ikuta, K. Okamoto, M. Koda, and H. Kawasaki, “Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C,” Journal of Gastroenterology, vol. 36, no. 6, pp. 399–406, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. J. G. McHutchison, L. M. Blatt, M. de Medina et al., “Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology,” Journal of Gastroenterology and Hepatology, vol. 15, no. 8, pp. 945–951, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Bourlière, G. Pénaranda, X. Adhoute, V. Oules, and P. Castellani, “Combining non-invasive methods for assessment of liver fibrosis,” Gastroentérologie Clinique et Biologique, vol. 32, no. 6, pp. S73–S79, 2008. View at Publisher · View at Google Scholar
  50. P. Halfon, M. Bourlière, G. Pénaranda et al., “Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus,” Comparative Hepatology, vol. 4, article 6, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. J. Guechot, A. Loria, L. Serfaty, P. Giral, J. Giboudeau, and R. Poupon, “Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapy,” Journal of Hepatology, vol. 22, no. 1, pp. 22–26, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. J. G. McHutchinson, L. M. Blau, M. de Medina et al., “Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology,” Journal of Gastroenterology and Hepatology, vol. 15, no. 8, pp. 945–951, 2000. View at Google Scholar
  53. K. M. Walsh, A. Fletcher, R. N. M. MacSween, and A. J. Morris, “Basement membrane peptides as markers of liver disease in chronic hepatitis C,” Journal of Hepatology, vol. 32, no. 2, pp. 325–330, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Kropf, A. M. Gressner, and A. Negwer, “Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases,” Clinical Chemistry, vol. 34, no. 10, pp. 2026–2030, 1988. View at Google Scholar · View at Scopus
  55. T. Körner, J. Kropf, and A. M. Gressner, “Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value,” Journal of Hepatology, vol. 25, no. 5, pp. 684–688, 1996. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Kondo, S. J. Miszputen, M. M. Borros Leite-mor, and E. R. Parise, “The predictive value of serum laminin for the risk of variceal bleeding related to portal pressure levels,” Hepato-Gastroenterology, vol. 42, no. 5, pp. 542–545, 1995. View at Google Scholar · View at Scopus
  57. O. Niemelä, J. Risteli, J. E. Blake, L. Risteli, K. V. Compton, and H. Orrego, “Markers of fibrogenesis and basement membrane formation in alcoholic liver disease. Relation to severity, presence of hepatitis, and alcohol intake,” Gastroenterology, vol. 98, no. 6, pp. 1612–1619, 1990. View at Google Scholar · View at Scopus
  58. J. S. Johansen, P. Christoffersen, S. Møller et al., “Serum YKL-40 is increased in patients with hepatic fibrosis,” Journal of Hepatology, vol. 32, no. 6, pp. 911–920, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. Y. Saitou, K. Shiraki, Y. Yamanaka et al., “Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease,” World Journal of Gastroenterology, vol. 11, no. 4, pp. 476–481, 2005. View at Google Scholar · View at Scopus
  60. J. Sun, “Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells,” Journal of Signal Transduction, vol. 2010, Article ID 985132, 7 pages, 2010. View at Publisher · View at Google Scholar
  61. Y. Murawaki, Y. Ikuta, Y. Idobe, and H. Kawasaki, “Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis,” Journal of Gastroenterology and Hepatology, vol. 14, no. 2, pp. 138–145, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. K. H. W. Boeker, C. I. Haberkorn, D. Michels, P. Flemming, M. P. Manns, and R. Lichtinghagen, “Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C,” Clinica Chimica Acta, vol. 316, no. 1-2, pp. 71–81, 2002. View at Publisher · View at Google Scholar · View at Scopus
  63. K. M. Walsh, P. Timms, S. Campbell, R. N. M. MacSween, and A. J. Morris, “Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C. Comparison using ROC analysis,” Digestive Diseases and Sciences, vol. 44, no. 3, pp. 624–630, 1999. View at Google Scholar · View at Scopus
  64. A. Hayasaka, N. Suzuki, N. Fujimoto et al., “Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma,” Hepatology, vol. 24, no. 5, pp. 1058–1062, 1996. View at Publisher · View at Google Scholar · View at Scopus
  65. G. Badra, M. Lotfy, A. El-Refaie et al., “Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients,” Acta Microbiologica et Immunologica Hungarica, vol. 57, no. 1, pp. 29–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. J. P. Iredale, S. Goddard, G. Murphy, R. C. Benyon, and M. J. P. Arthur, “Tissue inhibitor of metalloproteinase-1 and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes,” Clinical Science, vol. 89, no. 1, pp. 75–81, 1995. View at Google Scholar · View at Scopus
  67. R. C. Benyon, J. P. Iredale, S. Goddard, P. J. Winwood, and M. J. P. Arthur, “Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver,” Gastroenterology, vol. 110, no. 3, pp. 821–831, 1996. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Grigorescu, “Noninvasive biochemical markers of liver fibrosis,” Journal of Gastrointestinal and Liver Diseases, vol. 15, no. 2, pp. 149–159, 2006. View at Google Scholar · View at Scopus
  69. S. Kanzler, M. Baumann, P. Schirmacher et al., “Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-β,” Journal of Viral Hepatitis, vol. 8, no. 6, pp. 430–437, 2001. View at Publisher · View at Google Scholar · View at Scopus
  70. D. R. Nelson, R. P. Gonzalez-Peralta, K. Qian et al., “Transforming growth factor-β1 in chronic hepatitis C,” Journal of Viral Hepatitis, vol. 4, no. 1, pp. 29–35, 1997. View at Google Scholar · View at Scopus
  71. K.-I. Harada, G. Shiota, and H. Kawasaki, “Transforming growth factor-α and epidermal growth factor receptor in chronic liver disease and hepatocellular carcinoma,” Liver, vol. 19, no. 4, pp. 318–325, 1999. View at Publisher · View at Google Scholar · View at Scopus
  72. F. Marra, A. Gentilini, M. Pinzani et al., “Phosphatidylinositol 3-kinase is required for platelet-derived growth factor's actions on hepatic stellate cells,” Gastroenterology, vol. 112, no. 4, pp. 1297–1306, 1997. View at Publisher · View at Google Scholar · View at Scopus
  73. B.-B. Zhang, W.-M. Cai, H.-L. Weng et al., “Diagnostic value of platelet derived growth factor-BB, transforming growth factor-β1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood monoclear cells for hepatic fibrosis,” World Journal of Gastroenterology, vol. 9, no. 11, pp. 2490–2496, 2003. View at Google Scholar · View at Scopus
  74. T. Shiraishi, S. Morimoto, E. Koh, K. Fukuo, and T. Ogihara, “Increased release of platelet-derived growth factor from platelets in chronic liver disease,” European Journal of Clinical Chemistry and Clinical Biochemistry, vol. 32, no. 1, pp. 5–9, 1994. View at Google Scholar · View at Scopus
  75. P. Pradat, A. Alberti, T. Poynard et al., “Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study,” Hepatology, vol. 36, no. 4, pp. 973–977, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Prati, E. Taioli, A. Zanella et al., “Updated definitions of healthy ranges for serum alanine aminotransferase levels,” Annals of Internal Medicine, vol. 137, no. 1, pp. 1–9, 2002. View at Google Scholar · View at Scopus
  77. H. Akbar and H. Fallatah, “Serum ALT levels in a cohort of healthy blood donors and volunteers from Saudi Arabia: the influence of sex and body mass index,” Annals of Gastroenterology and Hepatology, vol. 1, pp. 13–19, 2010. View at Google Scholar
  78. J. W. Haukeland, L. T. Schreiner, I. Lorgen et al., “ASAT/ALAT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis,” Scandinavian Journal of Gastroenterology, vol. 43, no. 10, pp. 1241–1248, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. S. McPherson, S. F. Stewart, E. Henderson, A. D. Burt, and C. P. Day, “Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease,” Gut, vol. 59, no. 9, pp. 1265–1269, 2010. View at Publisher · View at Google Scholar
  80. E. Giannini, D. Risso, F. Botta et al., “Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease,” Archives of Internal Medicine, vol. 163, no. 2, pp. 218–224, 2003. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Sebastiani, A. Vario, M. Guido, and A. Alberti, “Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B,” World Journal of Gastroenterology, vol. 13, no. 4, pp. 525–531, 2007. View at Google Scholar · View at Scopus
  82. S. A. Harrison, D. Oliver, H. L. Arnold, S. Gogia, and B. A. Neuschwander-Tetri, “Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease,” Gut, vol. 57, no. 10, pp. 1441–1447, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Ruffillo, E. Fassio, E. Alvarez et al., “Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease,” Journal of Hepatology, vol. 54, no. 1, pp. 160–163, 2011. View at Publisher · View at Google Scholar · View at Scopus
  84. C.-T. Wai, J. K. Greenson, R. J. Fontana et al., “A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C,” Hepatology, vol. 38, no. 2, pp. 518–526, 2003. View at Publisher · View at Google Scholar · View at Scopus
  85. G. Sebastiani, A. Vario, M. Guido et al., “Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C,” Journal of Hepatology, vol. 44, no. 4, pp. 686–693, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. R. G. da Silva Jr., R. Fakhouri, T. V. B. do Nascimento, I. M. Santos, and L. M. M. Barbosa, “Aspartate aminotransferase-to-platelet ratio index for fibrosis and cirrhosis prediction in chronic hepatitis C patients,” Brazilian Journal of Infectious Diseases, vol. 12, no. 1, pp. 15–19, 2008. View at Google Scholar · View at Scopus
  87. A. Loaeza-del-Castillo, F. Paz-Pineda, E. Oviedo-Cárdenas, F. Sánchez-Ávila, and F. Vargas-Vorácková, “AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis,” Annals of Hepatology, vol. 7, no. 4, pp. 350–357, 2008. View at Google Scholar · View at Scopus
  88. N. Snyder, L. Gajula, S.-Y. Xiao et al., “APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C,” Journal of Clinical Gastroenterology, vol. 40, no. 6, pp. 535–542, 2006. View at Publisher · View at Google Scholar · View at Scopus
  89. N. Snyder, A. Nguyen, L. Gajula et al., “The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C,” Clinica Chimica Acta, vol. 381, no. 2, pp. 119–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
  90. Z.-H. Lin, Y.-N. Xin, Q.-J. Dong et al., “Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis,” Hepatology, vol. 53, no. 3, pp. 726–736, 2011. View at Publisher · View at Google Scholar · View at Scopus
  91. N. V. Chrysanthos, G. V. Papatheodoridis, S. Savvas et al., “Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis,” European Journal of Gastroenterology and Hepatology, vol. 18, no. 4, pp. 389–396, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. A. S. Lok, M. G. Ghany, Z. D. Goodman et al., “Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort,” Hepatology, vol. 42, no. 2, pp. 282–292, 2005. View at Publisher · View at Google Scholar
  93. P. Toniutto, C. Fabris, D. Bitetto et al., “Role of AST to platelet ratio index in the detection of liver fibrosis in patients with recurrent hepatitis C after liver transplantation,” Journal of Gastroenterology and Hepatology, vol. 22, no. 11, pp. 1904–1908, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. X. Forns, S. Ampurdanès, J. M. Llovet et al., “Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model,” Hepatology, vol. 36, no. 4, pp. 986–992, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Poynard, A. Aubert, P. Bedossa et al., “A simple biological index for detection of alcoholic liver disease in drinkers,” Gastroenterology, vol. 100, no. 5, pp. 1397–1402, 1991. View at Google Scholar · View at Scopus
  96. S. Naveau, T. Poynard, C. Benattar, P. Bedossa, and J.-C. Chaput, “Alpha-2-macroglobulin and hepatic fibrosis,” Digestive Diseases and Sciences, vol. 39, no. 11, pp. 2426–2432, 1994. View at Publisher · View at Google Scholar · View at Scopus
  97. F. Imbert-Bismut, V. Ratziu, L. Pieroni, F. Charlotte, Y. Benhamou, and T. Poynard, “Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study,” The Lancet, vol. 357, no. 9262, pp. 1069–1075, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. F. Imbert-Bismut, D. Messous, V. Thibault et al., “Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors,” Clinical Chemistry and Laboratory Medicine, vol. 42, no. 3, pp. 323–333, 2004. View at Publisher · View at Google Scholar
  99. T. Poynard, R. Morra, P. Ingiliz et al., “Biomarkers of liver fibrosis,” Advances in Clinical Chemistry, vol. 46, pp. 131–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Castera, “Non-invasive assessment of liver fibrosis in chronic hepatitis C,” Hepatology International, vol. 5, no. 2, pp. 625–634, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. V. Ratziu, J. Massard, F. Charlotte et al., “Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease,” BMC Gastroenterology, vol. 6, article 6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Poynard, V. de Ledinghen, J. P. Zarski et al., “Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard,” Journal of Hepatology, vol. 56, no. 3, pp. 541–548, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. T. Poynard, G. Lassailly, E. Diaz et al., “Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data,” PLoS ONE, vol. 7, no. 3, Article ID e30325, 2012. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Poynard, M. Munteanu, O. Deckmyn et al., “Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population,” Journal of Hepatology, vol. 57, no. 3, pp. 541–548, 2012. View at Publisher · View at Google Scholar
  105. P. Halfon, F. Imbert-Bismut, D. Messous et al., “A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease,” Comparative Hepatology, vol. 1, article 3, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Poynard, F. Imbert-Bismut, M. Munteanu et al., “Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C,” Comparative Hepatology, vol. 3, article 8, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Koda, Y. Matunaga, M. Kawakami, Y. Kishimoto, T. Suou, and Y. Murawaki, “Fibrolndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C,” Hepatology, vol. 45, no. 2, pp. 297–306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  108. P. Halfon, G. Penaranda, C. Renou, and M. Bourliere, “External validation of FibroIndex,” Hepatology, vol. 46, no. 1, pp. 280–281, 2007. View at Publisher · View at Google Scholar · View at Scopus
  109. R. K. Sterling, E. Lissen, N. Clumeck et al., “Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection,” Hepatology, vol. 43, no. 6, pp. 1317–1325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Vallet-Pichard, V. Mallet, B. Nalpas et al., “FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest,” Hepatology, vol. 46, no. 1, pp. 32–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. V. Mallet, V. Dhalluin-Venier, C. Roussin et al., “The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B,” Alimentary Pharmacology & Therapeutics, vol. 29, no. 4, pp. 409–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. A. G. Shah, A. Lydecker, K. Murray, B. N. Tetri, M. J. Contos, and A. J. Sanyal, “Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease,” Clinical Gastroenterology and Hepatology, vol. 7, no. 10, pp. 1104–1112, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. Y.-Y. Hsieh, S.-Y. Tung, I.-L. Lee et al., “FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis,” Chang Gung Medical Journal, vol. 32, no. 6, pp. 614–622, 2009. View at Google Scholar · View at Scopus
  114. Y.-Y. Hsieh, S.-Y. Tung, K. Lee et al., “Routine blood tests to predict liver fibrosis in chronic hepatitis C,” World Journal of Gastroenterology, vol. 18, no. 8, pp. 746–753, 2012. View at Publisher · View at Google Scholar · View at Scopus
  115. A. C. Tuyama and C. Y. Chang, “Non-alcoholic fatty liver disease,” Journal of Diabetes, vol. 4, no. 3, pp. 266–280, 2012. View at Publisher · View at Google Scholar
  116. P. Angulo, J. M. Hui, G. Marchesini et al., “The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD,” Hepatology, vol. 45, no. 4, pp. 846–854, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. T. Poynard, V. Ratziu, S. Naveau et al., “The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis,” Comparative Hepatology, vol. 4, article 10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Poynard, V. Ratziu, F. Charlotte et al., “Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease,” BMC Gastroenterology, vol. 6, article 34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  119. G. Lassailly, R. Caiazzo, A. Hollebecque et al., “Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity,” European Journal of Gastroenterology and Hepatology, vol. 23, no. 6, pp. 499–506, 2011. View at Publisher · View at Google Scholar · View at Scopus
  120. P. Calès, F. Oberti, S. Michalak et al., “A novel panel of blood markers to assess the degree of liver fibrosis,” Hepatology, vol. 42, no. 6, pp. 1373–1381, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. P. Calès, F. Lainé, J. Boursier et al., “Comparison of blood tests for liver fibrosis specific or not to NAFLD,” Journal of Hepatology, vol. 50, no. 1, pp. 165–173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  122. K. Patel, S. C. Gordon, I. Jacobson et al., “Evaluation of a panel of noninvasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients,” Journal of Hepatology, vol. 41, no. 6, pp. 935–942, 2004. View at Google Scholar
  123. K. Patel, D. R. Nelson, D. C. Rockey et al., “Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C,” Clinical Gastroenterology and Hepatology, vol. 6, no. 2, pp. 242–247, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. L. J. Jeffers, R. A. Cortes, P. A. Bejarano et al., “Prospective evaluation of FIBROSpect II for fibrosis detection in hepatitis C and B patients undergoing laparoscopic biopsy,” Gastroenterology & Hepatology, vol. 3, no. 5, pp. 367–376, 2007. View at Google Scholar · View at Scopus
  125. C. Christensen, D. Bruden, S. Livingston et al., “Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients,” Journal of Viral Hepatitis, vol. 13, no. 10, pp. 652–658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  126. T. B. Kelleher, S. H. Mehta, R. Bhaskar et al., “Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index,” Journal of Hepatology, vol. 43, no. 1, pp. 78–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  127. L. A. Adams, M. Bulsara, E. Rossi et al., “Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection,” Clinical Chemistry, vol. 51, no. 10, pp. 1867–1873, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. J. Guéchot, E. Lasnier, N. Sturm, A. Paris, and J.-P. Zarski, “Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort,” Clinica Chimica Acta, vol. 411, no. 1-2, pp. 86–91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. S. Naveau, G. Gaudé, A. Asnacios et al., “Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease,” Hepatology, vol. 49, no. 1, pp. 97–105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. W. M. C. Rosenberg, M. Voelker, R. Thiel et al., “Serum markers detect the presence of liver fibrosis: a cohort study,” Gastroenterology, vol. 127, no. 6, pp. 1704–1713, 2004. View at Publisher · View at Google Scholar · View at Scopus
  131. I. N. Guha, J. Parkes, P. Roderick et al., “Non-invasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers,” Hepatology, vol. 47, no. 2, pp. 455–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. G. Lalazar, O. Pappo, T. Hershcovici et al., “A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT,” Journal of Viral Hepatitis, vol. 15, no. 10, pp. 716–728, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. G. J.-H. Park, P. H. Katelaris, D. B. Jones, F. Seow, D. G. le Couteur, and M. C. Ngu, “Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function,” Hepatology, vol. 38, no. 5, pp. 1227–1236, 2003. View at Publisher · View at Google Scholar · View at Scopus
  134. L. Dinesen, W. F. Caspary, R. W. Chapman, C. F. Dietrich, C. Sarrazin, and B. Braden, “13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C,” Digestive and Liver Disease, vol. 40, no. 9, pp. 743–748, 2008. View at Publisher · View at Google Scholar · View at Scopus
  135. E. Petricoin, J. Wulfkuhle, V. Espina, and L. A. Liotta, “Clinical proteomics: revolutionizing disease detection and patient tailoring therapy,” Journal of Proteome Research, vol. 3, no. 2, pp. 209–217, 2004. View at Google Scholar
  136. N. Callewaert, H. van Vlierberghe, A. van Hecke, W. Laroy, J. Delanghe, and R. Contreras, “Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics,” Nature Medicine, vol. 10, no. 4, pp. 429–434, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. T. C. W. Poon, A. Y. Hui, H. L. Y. Chan et al., “Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study,” Clinical Chemistry, vol. 51, no. 2, pp. 328–335, 2005. View at Publisher · View at Google Scholar · View at Scopus
  138. B. Blomme, C. van Steenkiste, N. Callewaert, and H. van Vlierberghe, “Alteration of protein glycosylation in liver diseases,” Journal of Hepatology, vol. 50, no. 3, pp. 592–603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. R. K. T. Kam, T. C. W. Poon, H. L. Y. Chan, N. Wong, A. Y. Hui, and J. J. Y. Sung, “High-throughput quantitative profiling of serum N-glycome by MALDI-TOF mass spectrometry and N-glycomic fingerprint of liver fibrosis,” Clinical Chemistry, vol. 53, no. 7, pp. 1254–1263, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. T. J. S. Cross, V. Calvaruso, S. Maimone et al., “Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection,” Journal of Viral Hepatitis, vol. 17, no. 8, pp. 546–554, 2010. View at Publisher · View at Google Scholar · View at Scopus
  141. G. Bejarano-Redondo, M. Vergara, M. Gil et al., “Prospective evaluation of liver fibrosis in chronic viral hepatitis C infection using the Sabadell NIHCED (non-invasive hepatitis C related cirrhosis early detection) index,” Revista Espanola de Enfermedades Digestivas, vol. 101, no. 5, pp. 325–335, 2009. View at Google Scholar · View at Scopus
  142. W.-P. Liu, D.-J. Xu, L.-R. Zhao et al., “The prediction and validation of liver fibrosis by a noninvasive model and validation in patients with chronic hepatitis B,” Zhonghua Nei Ke Za Zhi, vol. 47, no. 4, pp. 308–312, 2008. View at Google Scholar · View at Scopus
  143. X.-L. Tu, Y.-Q. Xiao, and F. Chen, “A noninvasive model to predict histological liver cirrhosis in patients with chronic hepatitis B,” Zhonghua Gan Zang Bing Za Zhi, vol. 17, no. 1, pp. 28–32, 2009. View at Google Scholar · View at Scopus
  144. J.-X. Wang, B. Zhang, J.-K. Yu, J. Liu, M.-Q. Yang, and S. Zheng, “Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma,” Chinese Medical Journal, vol. 118, no. 15, pp. 1278–1284, 2005. View at Google Scholar · View at Scopus
  145. T. Göbel, S. Vordenwülbecke, K. Hauck, H. Fey, D. Häussinger, and A. Erhardt, “New multi protein patterns differentiative liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples,” World Journal of Gastroenterology, vol. 12, no. 47, pp. 7604–7612, 2006. View at Google Scholar · View at Scopus
  146. T. Trang, J. R. Petersen, and N. Snyder, “Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: comparison of the APRI and FIB-4 index,” Clinica Chimica Acta, vol. 397, no. 1-2, pp. 51–54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Bottero, K. Lacombe, J. Guéchot et al., “Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients,” Journal of Hepatology, vol. 50, no. 6, pp. 1074–1083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. G. Sebastiani, P. Halfon, L. Castera et al., “SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C,” Hepatology, vol. 49, no. 6, pp. 1821–1827, 2009. View at Publisher · View at Google Scholar · View at Scopus
  149. L. Castéra, G. Sebastiani, B. le Bail, V. de Lédinghen, P. Couzigou, and A. Alberti, “Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C,” Journal of Hepatology, vol. 52, no. 2, pp. 191–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. G. Sebastiani, A. Vario, M. Guido, and A. Alberti, “Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B,” World Journal of Gastroenterology, vol. 13, no. 4, pp. 525–531, 2007. View at Google Scholar · View at Scopus
  151. M. Bourliere, G. Penaranda, C. Renou et al., “Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies,” Journal of Viral Hepatitis, vol. 13, no. 10, pp. 659–670, 2006. View at Publisher · View at Google Scholar · View at Scopus
  152. V. Leroy, M.-N. Hilleret, N. Sturm et al., “Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C,” Journal of Hepatology, vol. 46, no. 5, pp. 775–782, 2007. View at Publisher · View at Google Scholar · View at Scopus
  153. M. Bourliere, G. Penaranda, D. Ouzan et al., “Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients,” Alimentary Pharmacology & Therapeutics, vol. 28, no. 4, pp. 458–467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  154. K. Patel, S. C. Gordon, I. Jacobson et al., “Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients,” Journal of Hepatology, vol. 41, no. 6, pp. 935–942, 2004. View at Publisher · View at Google Scholar · View at Scopus
  155. C. Lackner, G. Struber, B. Liegl et al., “Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C,” Hepatology, vol. 41, no. 6, pp. 1376–1382, 2005. View at Publisher · View at Google Scholar · View at Scopus
  156. C.-S. Lin, C.-S. Chang, S.-S. Yang, H.-Z. Yeh, and C.-W. Lin, “Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma,” Internal Medicine, vol. 47, no. 7, pp. 569–575, 2008. View at Publisher · View at Google Scholar · View at Scopus
  157. J. J. Carlson, K. V. Kowdley, S. D. Sullivan, S. D. Ramsey, and D. L. Veenstra, “An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis,” Journal of Gastroenterology and Hepatology, vol. 24, no. 5, pp. 786–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  158. H. Stefanescu, M. Grigorescu, M. Lupsor et al., “A new and simple algorithm for the noninvasive assessment of esophageal varices in cirrhotic patients using serum fibrosis markers and transient elastography,” Journal of Gastrointestinal and Liver Diseases, vol. 20, no. 1, pp. 57–64, 2011. View at Google Scholar · View at Scopus
  159. M. Zheng, W.-M. Cai, H.-L. Weng, and R.-H. Liu, “ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis,” World Journal of Gastroenterology, vol. 8, no. 6, pp. 1073–1076, 2002. View at Google Scholar · View at Scopus
  160. H. Lydatakis, I. P. Hager, E. Kostadelou, S. Mpousmpoulas, S. Pappas, and I. Diamantis, “Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease,” Liver International, vol. 26, no. 7, pp. 864–871, 2006. View at Publisher · View at Google Scholar · View at Scopus
  161. A. Suzuki, P. Angulo, J. Lymp, D. Li, S. Satomura, and K. Lindor, “Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease,” Liver International, vol. 25, no. 4, pp. 779–786, 2005. View at Publisher · View at Google Scholar · View at Scopus
  162. R. Malik, M. Chang, K. Bhaskar et al., “The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 24, no. 4, pp. 564–568, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. L. Castera and P. Bedossa, “How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?” Liver International, vol. 31, supplement 1, pp. 13–17, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. H. Razlan, N. M. Marzuki, M. L. Tai, A. S. Shamsul, T. Z. Ong, and S. Mahadeva, “Diagnostic value of the C methacetin breath test in various stages of chronic liver disease,” Gastroenterology Research and Practice, vol. 2011, Article ID 235796, 6 pages, 2011. View at Publisher · View at Google Scholar
  165. S. M. Kim, J. H. Sohn, T. Y. Kim et al., “Comparison of various noninvasive serum markers of liver fibrosis in chronic viral liver disease,” The Korean Journal of Hepatology, vol. 15, no. 4, pp. 454–463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Shaikh, M. S. Memon, H. Ghani, G. H. Baloch, M. Jaffery, and K. Shaikh, “Validation of three non-invasive markers in assessing the severity of liver fibrosis in chronic hepatitis C,” Journal of the College of Physicians and Surgeons Pakistan, vol. 19, no. 8, pp. 478–482, 2009. View at Google Scholar · View at Scopus
  167. R. C. Cheung, S. Currie, H. Shen et al., “Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice?” Journal of Clinical Gastroenterology, vol. 42, no. 7, pp. 827–834, 2008. View at Publisher · View at Google Scholar · View at Scopus
  168. P. Halfon, M. Munteanu, and T. Poynard, “FibroTest-ActiTest as a non-invasive marker of liver fibrosis,” Gastroenterologie Clinique et Biologique, vol. 32, no. 6, supplement 1, pp. 22–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  169. L. A. Adams, J. George, E. Bugianesi et al., “Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 26, no. 10, pp. 1536–1543, 2011. View at Publisher · View at Google Scholar
  170. R. Morra, M. Munteanu, P. Bedossa et al., “Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C,” Alimentary Pharmacology & Therapeutics, vol. 26, no. 6, pp. 847–858, 2007. View at Publisher · View at Google Scholar · View at Scopus
  171. C.-T. Wai, C. L. Cheng, A. Wee et al., “Non-invasive models for predicting histology in patients with chronic hepatitis B,” Liver International, vol. 26, no. 6, pp. 666–672, 2006. View at Publisher · View at Google Scholar · View at Scopus